Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-16-005832
Filing Date
2016-05-10
Accepted
2016-05-10 17:07:51
Documents
63
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q eprs-20160331x10q.htm 10-Q 1445944
2 EX-31.1 eprs-20160331ex311e2fbf8.htm EX-31.1 18404
3 EX-31.2 eprs-20160331ex312059b4b.htm EX-31.2 18458
4 EX-32.1 eprs-20160331ex3212c217e.htm EX-32.1 11782
  Complete submission text file 0001558370-16-005832.txt   5903713

Data Files

Seq Description Document Type Size
5 EX-101.INS eprs-20160331.xml EX-101.INS 1162985
6 EX-101.SCH eprs-20160331.xsd EX-101.SCH 50513
7 EX-101.CAL eprs-20160331_cal.xml EX-101.CAL 64208
8 EX-101.DEF eprs-20160331_def.xml EX-101.DEF 183464
9 EX-101.LAB eprs-20160331_lab.xml EX-101.LAB 429157
10 EX-101.PRE eprs-20160331_pre.xml EX-101.PRE 334765
Mailing Address 699 BOYLSTON ST 8TH FLOOR BOSTON MA 02116
Business Address 699 BOYLSTON ST 8TH FLOOR BOSTON MA 02116 (617) 600-3497
EPIRUS Biopharmaceuticals, Inc. (Filer) CIK: 0001135906 (see all company filings)

EIN.: 043514457 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51171 | Film No.: 161636734
SIC: 2834 Pharmaceutical Preparations